SEC Comment Letter 0000000000-23-000688 to Zeo ScientifiX, Inc. (ZEOX)
Zeo ScientifiX, Inc.
Date: Jan. 20, 2023 · CIK: 0001557376 · Accession: 0000000000-23-000688
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo January 20, 2023 Ian Bothwell CFO Skycrest Holdings, LLC 1930 Harrison Street, Suite 204 Hollywood, FL 33020 Re:Organicell Regenerative Medicine, Inc. Schedule 13D filed by Skycrest Holdings, LLC Filed December 30, 2022 File No. 005-87575 Dear Ian Bothwell: We have reviewed the above-captioned filing, and have the following comments. In some of our comments, we may ask to be provided with information so we may better understand the disclosure. Please respond to this letter by amending the filing or by providing the requested information. If a belief exists that our comments do not apply to your facts and circumstances or that an amendment is inappropriate, please advise us why in a response. After reviewing any amendment to the filing and any information provided in response to these comments, we may have additional comments Schedule 13D filed December 30, 2022 General 1.We note the date of the event reported as requiring the filing of the Schedule 13D was August 16, 2022. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule 13D within 10 days after the acquisition of more than five percent of a class of equity securities specified in Rule 13d-1(i). Based on the August 16, 2022 event date, the December 30, 2022 filing was not timely filed. Please advise us why the Schedule 13D was not filed within the required 10 days after the acquisition. 2.Please provide the required qualitative disclosure narrative for each item requirement of Schedule 13D. See Rule 13d-1(a) and Instruction A. to Schedule 13D, which explains that the item numbers and captions shall be provided together with the answers to the items but the text of the items is to be omitted. Alternatively, if an item is inapplicable or an answer is in the negative, so state as required by Instruction A.
FirstName LastNameIan Bothwell Comapany NameSkycrest Holdings, LLC January 20, 2023 Page 2 FirstName LastName Ian Bothwell Skycrest Holdings, LLC January 20, 2023 Page 2 We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please direct any questions to Michael Killoy at 202-551-7576 or Nicholas Panos at 202- 551-3266 Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions
Show Raw Text
United States securities and exchange commission logo
January 20, 2023
Ian Bothwell
CFO
Skycrest Holdings, LLC
1930 Harrison Street, Suite 204
Hollywood, FL 33020
Re:Organicell Regenerative Medicine, Inc.
Schedule 13D filed by Skycrest Holdings, LLC
Filed December 30, 2022
File No. 005-87575
Dear Ian Bothwell:
We have reviewed the above-captioned filing, and have the following comments. In some
of our comments, we may ask to be provided with information so we may better understand
the disclosure.
Please respond to this letter by amending the filing or by providing the requested
information. If a belief exists that our comments do not apply to your facts and circumstances or
that an amendment is inappropriate, please advise us why in a response.
After reviewing any amendment to the filing and any information provided in response to
these comments, we may have additional comments
Schedule 13D filed December 30, 2022
General
1.We note the date of the event reported as requiring the filing of the Schedule 13D was
August 16, 2022. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule
13D within 10 days after the acquisition of more than five percent of a class of equity
securities specified in Rule 13d-1(i). Based on the August 16, 2022 event date, the
December 30, 2022 filing was not timely filed. Please advise us why the Schedule 13D
was not filed within the required 10 days after the acquisition.
2.Please provide the required qualitative disclosure narrative for each item requirement of
Schedule 13D. See Rule 13d-1(a) and Instruction A. to Schedule 13D, which explains
that the item numbers and captions shall be provided together with the answers to the
items but the text of the items is to be omitted. Alternatively, if an item is inapplicable or
an answer is in the negative, so state as required by Instruction A.
FirstName LastNameIan Bothwell
Comapany NameSkycrest Holdings, LLC
January 20, 2023 Page 2
FirstName LastName
Ian Bothwell
Skycrest Holdings, LLC
January 20, 2023
Page 2
We remind you that the filing persons are responsible for the accuracy and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please direct any questions to Michael Killoy at 202-551-7576 or Nicholas Panos at 202-
551-3266
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions